Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Operations (2016 - 2025)

Lineage Cell Therapeutics' Cash from Operations history spans 16 years, with the latest figure at 4878000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 23.13% year-over-year to 4878000.0; the TTM value through Dec 2025 reached 18919000.0, up 18.07%, while the annual FY2025 figure was 18919000.0, 18.07% up from the prior year.
  • Cash from Operations reached 4878000.0 in Q4 2025 per LCTX's latest filing, down from 3616000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 21904000.0 in Q1 2022 to a low of 11242000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 4653950.0, with a median of 5661000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: surged 395.04% in 2022, then crashed 151.32% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 5873000.0 in 2021, then tumbled by 41.38% to 8303000.0 in 2022, then grew by 27.51% to 6019000.0 in 2023, then dropped by 5.43% to 6346000.0 in 2024, then grew by 23.13% to 4878000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Cash from Operations are 4878000.0 (Q4 2025), 3616000.0 (Q3 2025), and 5539000.0 (Q2 2025).